ABSTRACT
La disfunción eréctil es una patología de alta frecuencia, especialmente en población masculina de mayor edad. La erección está dada fundamentalmente por la activación del sistema parasimpático, por acción del óxido nítrico y aumento de GMP cíclico; es así como fármacos como Sildenafil que disminuyen la eliminación de GMP cíclico al inhibir la actividad de la 5 fosfodiesterasa, potencian la mantención de dicha erección. Recientemente se lanzó al mercado la presentación masticable de este fármaco, lo que eliminaría el primer paso hepático de la presentación oral clásica. En este estudio, se analizaron 20 pacientes con disfunción eréctil sin comorbilidad asociada, los que consumieron la forma masticable; con el objetivo de evaluar eficacia clínica y efectos adversos. Los resultados obtenidos muestran que existe un alto grado de satisfacción de usuario en cuanto a forma de presentación, tiempo de administración y eficacia, y que los efectos adversos no difieren a los de la presentación tradicional. Se propone realizar estudios prospectivos comparativos de ambas presentaciones y otros inhibidores de la 5 fosfodiesterasa, para confirmar estos resultados preliminares.
Erectil dysfunction is a very frequent pathology in the elderly male. Erections are activated mainly by the parasympathic system, caused by nitric oxide and the increase of cyclic cGMP; it is because of this that drugs like Sildenafil improve partial erections by inhibiting the enzyme that facilitates the reduction of cyclic guanosine monophosphate (cGMP). Recently a chewable new form of this drug entered the market,it is deemed to avoid hepatic transformation of the drug. In this study we analyzed 20 patients witherectile dysfunction without other associated comorbidities that were treated with this drug. Results showed that patients were highly satisfied with the form of presentation, the dosage regimen, and efficacy. Side effects are no different from the other and more traditional version. We will conduct prospective comparative studies of both versions of the drugs and other inhibitors of the cGMP specific phosphodiesterase type 5,to confirm these preliminary results.
Subject(s)
Humans , Male , Erectile Dysfunction/drug therapy , Phosphodiesterase Inhibitors/administration & dosage , Piperazines/administration & dosage , Purines/administration & dosage , Sulfones/administration & dosage , Administration, Oral , Prospective Studies , Phosphodiesterase Inhibitors/adverse effects , Data Collection , Patient SatisfactionABSTRACT
Most research on hygienic behavior has recorded the time taken by the colony to remove an experimental amount of dead brood, usually after one or two days. We evaluated the time that hygienic (H) and non-hygienic (NH) honey bees take to uncap and remove dead brood in observation hives after the brood was killed using the pin-killing assay. Four experimental colonies were selected as the extreme cases among 108 original colonies. Thirty brood cells were perforated with a pin in two H and two NH colonies and observations were made after 1, 2, 3, 4, 5, 6, and 24 h. Different stages of uncapping and removing were recorded. Differences in uncapping and removal between H and NH colonies were significant for all comparisons made at the different times after perforation. Using observation hives one obtains a better and faster discrimination between H and NH colonies than in full size colonies. It is possible to differentiate H and NH within a few hours after perforating the cells